April 2011

MacroGenics publishes DART data

Friday, April 29, 2011

MacroGenics, a biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, has published in the journal Blood preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

[Read More]

US HIFU reports positive results for prostate cancer trial

Friday, April 29, 2011

US HIFU, a minimally invasive high intensity focused ultrasound (HIFU) technologies company and manufacturer of the Sonablate 500  medical device, has results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate.

[Read More]

Shire reports positive results from investigative use of Vyvanse

Friday, April 29, 2011

Global biopharmaceutical company Shire reports positive results from a signal-finding study of Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) assessing the drug’s effect in a prospective examination of adults with negative symptom predominant schizophrenia. This study met its pre-defined primary end points.

[Read More]